JP2005518439A - 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 - Google Patents

抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 Download PDF

Info

Publication number
JP2005518439A
JP2005518439A JP2003570882A JP2003570882A JP2005518439A JP 2005518439 A JP2005518439 A JP 2005518439A JP 2003570882 A JP2003570882 A JP 2003570882A JP 2003570882 A JP2003570882 A JP 2003570882A JP 2005518439 A JP2005518439 A JP 2005518439A
Authority
JP
Japan
Prior art keywords
migraine
topiramate
treatment
group
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003570882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518439A5 (cg-RX-API-DMAC7.html
Inventor
リビングストン,イアン・アール
Original Assignee
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド filed Critical オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド
Publication of JP2005518439A publication Critical patent/JP2005518439A/ja
Publication of JP2005518439A5 publication Critical patent/JP2005518439A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003570882A 2002-02-26 2003-02-25 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 Pending JP2005518439A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (2)

Publication Number Publication Date
JP2005518439A true JP2005518439A (ja) 2005-06-23
JP2005518439A5 JP2005518439A5 (cg-RX-API-DMAC7.html) 2006-04-06

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570882A Pending JP2005518439A (ja) 2002-02-26 2003-02-25 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬

Country Status (18)

Country Link
US (2) US20030225002A1 (cg-RX-API-DMAC7.html)
EP (1) EP1478400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005518439A (cg-RX-API-DMAC7.html)
KR (1) KR101008326B1 (cg-RX-API-DMAC7.html)
CN (1) CN100352506C (cg-RX-API-DMAC7.html)
AU (1) AU2003213242A1 (cg-RX-API-DMAC7.html)
BR (1) BR0307951A (cg-RX-API-DMAC7.html)
CA (1) CA2419989A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040846A2 (cg-RX-API-DMAC7.html)
IL (2) IL163720A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008259A (cg-RX-API-DMAC7.html)
NO (1) NO20043984L (cg-RX-API-DMAC7.html)
NZ (1) NZ534874A (cg-RX-API-DMAC7.html)
PL (1) PL372393A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126093A (cg-RX-API-DMAC7.html)
UA (1) UA81110C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003072138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407729B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007077147A (ja) * 2005-09-09 2007-03-29 Lab Servier アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
JP2012502909A (ja) * 2008-09-17 2012-02-02 ザ マクリーン ホスピタル コーポレーション 群発頭痛障害を治療するための方法及びキット

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
JP2007523176A (ja) * 2004-02-17 2007-08-16 セプラコア インコーポレーテッド シタロプラム、エスシタロプラム又はシタロプラム代謝物質を用いる片頭痛又は頭痛疾患の治療又は病気の予防法
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
EP2023894A4 (en) * 2006-04-25 2010-10-20 Applied Pharma Res FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2018067330A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
DK3955933T3 (da) * 2019-04-15 2024-02-12 Vistagen Therapeutics Inc Behandling af migræne

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066943A1 (en) * 1998-06-25 1999-12-29 Curt Hendrix Dietary supplement for supporting cerebrovascular tone
WO2000018405A1 (en) * 1997-09-25 2000-04-06 Pharmagene Laboratories Ltd. Use of prostanoid antagonists for the treatment of primary headache disorders
JP2000508341A (ja) * 1996-10-09 2000-07-04 アルゴス ファーマシューティカル コーポレーション 片頭痛の治療法及び薬効の強化組成物
JP2001513803A (ja) * 1997-03-03 2001-09-04 ラボラトワール ルミレア 植物抽出物組成物、その製造方法、及びそれを含む医薬組成物
JP2001518097A (ja) * 1997-03-24 2001-10-09 アドロール コーポレーション 片頭痛の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
CN1182845C (zh) * 1999-01-19 2005-01-05 奥索-麦克尼尔药品公司 用于治疗集束性头痛的抗惊厥剂衍生物
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000508341A (ja) * 1996-10-09 2000-07-04 アルゴス ファーマシューティカル コーポレーション 片頭痛の治療法及び薬効の強化組成物
JP2001513803A (ja) * 1997-03-03 2001-09-04 ラボラトワール ルミレア 植物抽出物組成物、その製造方法、及びそれを含む医薬組成物
JP2001518097A (ja) * 1997-03-24 2001-10-09 アドロール コーポレーション 片頭痛の治療方法
WO2000018405A1 (en) * 1997-09-25 2000-04-06 Pharmagene Laboratories Ltd. Use of prostanoid antagonists for the treatment of primary headache disorders
WO1999066943A1 (en) * 1998-06-25 1999-12-29 Curt Hendrix Dietary supplement for supporting cerebrovascular tone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CNS DRUGS, vol. 11, no. 1, JPN6009045575, 1999, pages 61 - 82, ISSN: 0001410252 *
L.J.STEPHEN ET AL., THE LANCET, vol. 351, no. 9107, JPN5004010755, 1998, pages 958 - 959, ISSN: 0001410250 *
L.S.STEPHEN ET AL., EPILEPSIA, vol. 41, no. 8, JPN5004010757, 2000, pages 977 - 980, ISSN: 0001410251 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007077147A (ja) * 2005-09-09 2007-03-29 Lab Servier アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
JP2011088919A (ja) * 2005-09-09 2011-05-06 Lab Servier アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
JP2012502909A (ja) * 2008-09-17 2012-02-02 ザ マクリーン ホスピタル コーポレーション 群発頭痛障害を治療するための方法及びキット

Also Published As

Publication number Publication date
CN100352506C (zh) 2007-12-05
EP1478400A1 (en) 2004-11-24
CN1646168A (zh) 2005-07-27
RU2004126093A (ru) 2005-04-10
IL163720A (en) 2012-06-28
US20030225002A1 (en) 2003-12-04
IL163720A0 (en) 2005-12-18
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
NZ534874A (en) 2007-03-30
MXPA04008259A (es) 2005-05-27
AU2003213242A1 (en) 2003-09-09
KR20040091074A (ko) 2004-10-27
ZA200407729B (en) 2006-06-28
BR0307951A (pt) 2004-12-21
WO2003072138A1 (en) 2003-09-04
UA81110C2 (en) 2007-12-10
HRP20040846A2 (en) 2005-06-30
KR101008326B1 (ko) 2011-01-13
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
CA2419989A1 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
KR101008326B1 (ko) 항경련제 유도체 및 항-편두통제를 포함하는 편두통치료를 위한 공-요법
Vinik et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies
US8461148B2 (en) Use of memantine (namenda) to treat autism, compulsivity and impulsivity
Silberstein et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study
US6627653B2 (en) Anticonvulsant derivatives useful for the treatment of depression
KR102615486B1 (ko) 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
JP2023071832A (ja) フェンフルラミンを用いるドゥーゼ症候群の治療方法
Wheatley et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
JP2023116729A (ja) フェンフルラミンによる認知機能の改善方法
KR20030016205A (ko) Cns 질환의 치료를 위한 단독 또는 조합된피롤리딘아세트아미드 유도체
JP2004527553A (ja) 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
UA75580C2 (uk) Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
WO2000072841A1 (en) Compounds and methods for the treatment of post traumatic stress disorder
JP2016512561A (ja) オピオイド/トール様受容体4アンタゴニスト、そのデキストロエナンチオマーを含む、痛みを軽減するための組成物、及びそのための使用方法
JP2022548892A (ja) てんかん患者をフェンフルラミンで治療する方法
JP2010508279A (ja) 破壊的行動障害の処置法
HK1080731B (en) Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments
US20030092636A1 (en) Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
Sacchetti et al. Paroxetine versus amitriptyline in patients with recurrent major depression: A double-blind trial
KR20250053188A (ko) 주요 우울 장애의 애주번트 치료를 위한 울로타론트
Isaac S. 11.04 Can we identify subgroups for targeted adjunctive treatment?
Ferguson High-Dose Ranges of Gepirone-ER Compared With Placebo in the Treatment of Depressed
HK40009699B (en) Anavex 2-73, anavex 1-41 or anavex 19-144 for the treatment of maintenance insomnia
HK40009699A (en) Anavex 2-73, anavex 1-41 or anavex 19-144 for the treatment of maintenance insomnia
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060215

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511